Old active ingredients in new medicinal products: is the regulatory path coherent with patients’ expectations?-Reference-Cited by-同舟云学术

Old active ingredients in new medicinal products: is the regulatory path coherent with patients’ expectations?

Published:2020-08 Issue:8 Volume:25 Page:1337-1347
ISSN:1359-6446
Container-title:Drug Discovery Today
language:en
Short-container-title:Drug Discovery Today

Author:

Minghetti Paola,Musazzi Umberto M.,Casiraghi Antonella,Rocco Paolo

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology

Reference80 articles.

1. M4 Common Technical Document (CTD);ICH,2004

2. Innovation in the pharmaceutical industries: new estimates of R&D costs;Di Masi;J. Health Econ.,2016

3. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code Relating to Medicinal Products for Human Use, as Amended by Dir. 2004/27/EC. Article 10;EU,2001

4. Frequently Asked Questions on Patents and Exclusivity;FDA,2020

5. An update on the first decade of the European centralized procedure: how many innovative drugs?;Motola;Br. J. Clin. Pharmacol.,2006

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Equivalence assessment of creams with quali-quantitative differences in light of the EMA and FDA regulatory framework;European Journal of Pharmaceutical Sciences;2024-04

2. Cases of drug repositioning in children's orphan drugs: Licenced drugs versus unlicenced magistral preparations;Journal of Drug Delivery Science and Technology;2023-04

3. Repurposing of parenterally administered active substances used to treat pain both systemically and locally;Drug Discovery Today;2022-10

4. Design and development of topical liposomal formulations in a regulatory perspective;Drug Delivery and Translational Research;2021-11-09

5. Regulatory density as a means to refine current regulatory approaches for increasingly complex medicines;Drug Discovery Today;2021-10